부산대학교 도서관

The review of Huang et al., 2022 [[11]] shows that the DNA damage response (DDR) is a valuable target for the development of anti-cancer therapies. Although deficiency in DDR genes induces genomic instability and facilitates cancer development, DDR can, conversely, also help cancer cells to resist therapy-induced DNA damage. The goal of cancer therapy is to target tumor cells by exploiting the differences from normal cells to avoid side effects. They find that while in normal cells Zn supplementation protects cells from damage accumulation and improves the DDR, in AML cells, Zn potentiates the genotoxicity of DNA-damaging agents by promoting cytotoxic and antiproliferative effects. [Extracted from the article]